And yet, there has been no national plan to facilitate the widespread and safe delivery to eligible Americans of GLP-1s like Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide)
Due to the dramatic benefits observed with these medications, barely a day goes by without health care providers and consumer-aimed headlines either raving or raising concerns about them
If the incoming administration backs the proposal, this requirement could become law in 2026
Key Growth Drivers: Increasing global obesity and diabetes burden Superior clinical efficacy in weight management Expanding indications including cardiovascular disease, MASH, CKD, and sleep apnea Growing adoption of oral GLP-1 medications Significant investments from leading pharmaceutical companies AI-powered drug discovery and innovation Expanding healthcare reimbursement and patient access As pharmaceutical leaders continue investing billions into next-generation GLP-1 therapies, this market is expected to reshape the future of cardiometabolic healthcare through 2035
This clinical approach is more aligned with current research than the outdated check FSH once methodology
Third-Party Testing We selected NMN supplements that have been verified through third-party testing for safety, purity, and label accuracy